BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 10941565)

  • 1. Systemic chemotherapy.
    Klimek VM; Wolchok JD; Chapman PB; Houghton AN; Hwu WJ
    Clin Plast Surg; 2000 Jul; 27(3):451-61, ix-x. PubMed ID: 10941565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of metastasized malignant melanoma].
    Kamanabrou D
    Praxis (Bern 1994); 2001 Mar; 90(10):391-6. PubMed ID: 11305184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chemotherapy of malignant melanoma--current status].
    Karg C; Garbe C; Orfanos CE
    Hautarzt; 1990 Feb; 41(2):56-65. PubMed ID: 2180855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-2 for the treatment of melanoma.
    Tarhini AA; Agarwala SS
    Curr Opin Investig Drugs; 2005 Dec; 6(12):1234-9. PubMed ID: 16370388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatments for metastatic melanoma: synthesis of evidence from randomized trials.
    Lui P; Cashin R; Machado M; Hemels M; Corey-Lisle PK; Einarson TR
    Cancer Treat Rev; 2007 Dec; 33(8):665-80. PubMed ID: 17919823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dacarbazine DTIC and carboplatin as an outpatient treatment for disseminated malignant melanoma.
    Nieboer P; Mulder NH; Van Der Graaf WT; Willemse PH; Hospers GA
    Anticancer Res; 2001; 21(4B):3115-6. PubMed ID: 11712820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy for metastatic melanoma: time for a change?
    Gogas HJ; Kirkwood JM; Sondak VK
    Cancer; 2007 Feb; 109(3):455-64. PubMed ID: 17200963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
    Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
    Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival.
    Bedikian AY; Johnson MM; Warneke CL; McIntyre S; Papadopoulos N; Hwu WJ; Kim K; Hwu P
    J Immunotoxicol; 2008 Apr; 5(2):201-7. PubMed ID: 18569391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy for metastatic melanoma.
    MandarĂ  M; Nortilli R; Sava T; Cetto GL
    Expert Rev Anticancer Ther; 2006 Jan; 6(1):121-30. PubMed ID: 16375649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment for metastatic malignant melanoma: old drugs and new strategies.
    Mouawad R; Sebert M; Michels J; Bloch J; Spano JP; Khayat D
    Crit Rev Oncol Hematol; 2010 Apr; 74(1):27-39. PubMed ID: 19781957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Organ- and treatment-specific local response rates to systemic and local treatment modalities in stage IV melanoma.
    Richtig E; Ludwig R; Kerl H; Smolle J
    Br J Dermatol; 2005 Nov; 153(5):925-31. PubMed ID: 16225601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [DTIC in malignant melanoma: a perspective (author's transl)].
    Kokoschka EM
    Wien Klin Wochenschr; 1978 Dec; 90(24):870-4. PubMed ID: 369152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
    Gibbs P; Anderson C; Pearlman N; LaClaire S; Becker M; Gatlin K; O'Driscoll M; Stephens J; Gonzalez R
    Cancer; 2002 Jan; 94(2):470-6. PubMed ID: 11900232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma.
    Kim KB; Eton O; East MJ; Hodges C; Papadopoulos NE; Grimm EA; Bedikian AY
    Cancer; 2004 Aug; 101(3):596-603. PubMed ID: 15274073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy and targeted therapy combinations in advanced melanoma.
    Flaherty KT
    Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2366s-2370s. PubMed ID: 16609060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy of advanced prostatic carcinoma.
    Millikan RE
    Semin Oncol; 1999 Apr; 26(2):185-91. PubMed ID: 10597729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
    Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting.
    Garbe C; Hauschild A; Volkenandt M; Schadendorf D; Stolz W; Reinhold U; Kortmann RD; Kettelhack C; Frerich B; Keilholz U; Dummer R; Sebastian G; Tilgen W; Schuler G; Mackensen A; Kaufmann R
    Melanoma Res; 2008 Apr; 18(2):152-60. PubMed ID: 18337653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?
    Eggermont AM; Kirkwood JM
    Eur J Cancer; 2004 Aug; 40(12):1825-36. PubMed ID: 15288283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.